Source link : https://www.newshealth.biz/health-news/fda-oks-once-daily-injection-for-hypoparathyroidism/
After rejecting it a year ago, the FDA approved once-daily palopegteriparatide (Yorvipath) for adults with hypoparathyroidism, drugmaker Ascendis Pharma announced on Monday. Injectable palopegteriparatide is a prodrug of parathyroid hormone (PTH[1-34]) that is designed to provide sustained exposure to the hormone over 24 hours. Parathyroid hormone is the primary regulator of calcium and phosphate balance […]
Author : News Health
Publish date : 2024-08-12 17:56:41
Copyright for syndicated content belongs to the linked Source.
Categories